The CINCH-FMR Post-Market Registry: Percutaneous Repair in Functional Mitral Regurgitation

• Sponsor: Cardiac Dimensions, Inc. (Industry)
• Overall Status: Enrolling by invitation
• CT.gov ID: NCT05677568
• Collaborator: (none)
• Enrollment: 150
• Location: 1
• Anticipated Duration (Months): 126.2
• Patients Per Site Per Month: 1.2

Study Details

Study Description

Brief Summary

This is a retrospective and prospective, multi-center, post-market observational registry study. The primary objective of this post market registry is to continue to evaluate the long term safety and performance of the Carillon® Mitral Contour System® (CMCS) in a commercial (post market) setting.

Condition or Disease	Intervention/Treatment	Phase
Functional Mitral Regurgitation; Mitral Regurgitation	Device: Carillon Mitral Contour System

Detailed Description

There are more than 22 million people worldwide with heart failure, including 5.3 million in the United States . Functional mitral regurgitation (MR), leakage of the mitral valve due to dilation of the left ventricle and annulus, occurs as a consequence of Heart Failure. Cardiac Dimensions has developed proprietary technology designed to address functional mitral regurgitation in a minimally invasive manner.

Previous studies have established that the Carillon® therapy has caused a significant reduction in functional MR. This reduction in MR results in clinically significant improvements in exercise tolerance, quality of life, and thus overall function in a symptomatic heart failure population.

To supplement the findings from these previous studies, Cardiac Dimensions is conducting this post-market registry of the Carillon® Mitral Contour System® (CMCS) in patients with functional mitral regurgitation. This registry is a retrospective and prospective, multi-center, clinical registry designed to further characterize the acute and long-term safety and performance profile of the CMCS. Up to 150 implanted patients will be enrolled at up to 40 centers located in the European Union and countries that recognize the CE-mark as a valid marketing authorization.

Patients enrolled in the registry have received the Carillon implant and will be assessed to document the long-term safety and performance of the device. These patients will be followed according to routine standard of care post procedure follow up assessments.

Study Design

• Study Type: Observational [Patient Registry]
• Anticipated Enrollment: 150 participants
• Observational Model: Case-Only
• Time Perspective: Other
• Official Title: The CINCH-FMR Post-Market Registry: Percutaneous Repair in Functional Mitral Regurgitation
• Actual Study Start Date: Jun 24, 2017
• Anticipated Primary Completion Date: Dec 30, 2025
• Anticipated Study Completion Date: Dec 31, 2027

Arms and Interventions

Arm	Intervention/Treatment
Prospective "Prospective" patients are identified prior to undergoing the Carillon procedure and are only enrolled after being successfully implanted with the Carillon device (prior to hospital discharge). Prospective patients will have applicable medical history and details of the Carillon implant procedure collected from medical records. After the patient is discharged, the patient's primary care specialist (cardiologist) and clinical investigation site staff will coordinate follow-up evaluations. Patients will be evaluated at one (1), six (6), twelve (12) months per standard of care and with annual contact for an additional four (4) years, for a total of five (5) years to assess long-term safety of the Carillon implant.	Device: Carillon Mitral Contour System; The Cardiac Dimensions CARILLON Mitral Contour System (CMCS) is a medical device and consists of the following components: A proprietary implant intended for permanent placement in the coronary sinus (CS)/great cardiac vein (GCV) A catheter-based delivery system which consists of a curved CMCS delivery catheter (3.2mm outer diameter) and a handle assembly A sizing catheter to enable the physician to estimate the overall CS/GCV dimensions so that an appropriately sized implant may be selected The implant is attached to the handle assembly and is delivered through the CMCS delivery catheter to the coronary vein along the posterolateral aspect of the mitral annulus. The implant is designed to re-shape the mitral annulus to reduce annular dilation and mitral regurgitation.; Other Names: Cardiac Dimensions CMCS
Retrospective/Prospective "Retrospective/Prospective" patients are implanted with the Carillon device and are currently being followed-up per standard of care. These patients will have applicable data collected from their medical records, including medical history, data about the Carillon procedure and follow-up visit data done since receiving the Carillon implant. They will be evaluated prospectively per standard of care follow-up through five (5) years post-implant to assess long-term safety of the Carillon implant.	Device: Carillon Mitral Contour System; The Cardiac Dimensions CARILLON Mitral Contour System (CMCS) is a medical device and consists of the following components: A proprietary implant intended for permanent placement in the coronary sinus (CS)/great cardiac vein (GCV) A catheter-based delivery system which consists of a curved CMCS delivery catheter (3.2mm outer diameter) and a handle assembly A sizing catheter to enable the physician to estimate the overall CS/GCV dimensions so that an appropriately sized implant may be selected The implant is attached to the handle assembly and is delivered through the CMCS delivery catheter to the coronary vein along the posterolateral aspect of the mitral annulus. The implant is designed to re-shape the mitral annulus to reduce annular dilation and mitral regurgitation.; Other Names: Cardiac Dimensions CMCS

Outcome Measures

Primary Outcome Measures

1. Death [6 months]

   All cause mortality including cardiovascular and non-cardiovascular death

2. Death [12 months]

   All cause mortality including cardiovascular and non-cardiovascular death

3. Death [24 months]

   All cause mortality including cardiovascular and non-cardiovascular death

4. Death [3 years]

   All cause mortality including cardiovascular and non-cardiovascular death

5. Death [4 years]

   All cause mortality including cardiovascular and non-cardiovascular death

6. Death [5 years]

   All cause mortality including cardiovascular and non-cardiovascular death

7. Serious adverse events [6 months]

   Number of procedure related or device related serious adverse events

8. Serious adverse events [12 months]

   Number of procedure related or device related serious adverse events

9. Change in New York Heart Association (NYHA) classification [6, 12, and 24 months, and 3, 4, and 5 years]

   Change in New York Heart Association (NYHA) Functional Classification at 6, 12, and 24 months, and 3, 4, and 5 years

10. Rate of Heart Failure Hospitalizations [6 months]

    Rate of hospitalization for heart failure

11. Rate of Heart Failure Hospitalizations [12 months]

    Rate of hospitalization for heart failure

12. Rate of Heart Failure Hospitalizations [24 months]

    Rate of hospitalization for heart failure

13. Rate of Heart Failure Hospitalizations [3 years]

    Rate of hospitalization for heart failure

14. Rate of Heart Failure Hospitalizations [4 years]

    Rate of hospitalization for heart failure

15. Rate of Heart Failure Hospitalizations [5 years]

    Rate of hospitalization for heart failure

Secondary Outcome Measures

1. Change of MR Severity via Quantitative MR Variable: regurgitant volume (mL) [6, 12, and 24 months, and 3, 4, and 5 years]

   change in MR severity based in regurgitant volume as assessed by echocardiography in hospital, 6, 12, and 24 months, and 3, 4, and 5 years, in accordance with American Society of Echocardiography guidelines, compared to baseline.

2. Change of MR Severity via Quantitative MR Variable: regurgitant fraction (%) [6, 12, and 24 months, and 3, 4, and 5 years]

   change in MR severity based on regurgitant fraction (%) as assessed by echocardiography in hospital, 6, 12, and 24 months, and 3, 4, and 5 years, in accordance with American Society of Echocardiography guidelines, compared to baseline.

3. Change of MR Severity via Quantitative MR Variable: effective regurgitant orifice area (cm2 EROA) [6, 12, and 24 months, and 3, 4, and 5 years]

   change in MR severity based on effective regurgitant orifice area (cm2, EROA) as assessed by by Proximal Isovelocity Surface Area (PISA) via echocardiography in hospital, 6, 12, and 24 months, and 3, 4, and 5 years, in accordance with American Society of Echocardiography guidelines, compared to baseline.

4. Change of MR severity: Semi-Quantitative Parameter: Change in vena contract width [6, 12, and 24 months, and 3, 4, and 5 years]

   Change in vena contract width MR severity as assessed by echocardiography in hospital 6, 12, and 24 months, and 3, 4, and 5 years, in accordance with American Society of Echocardiography guidelines, compared to baseline.

5. Change of MR severity: Semi-Quantitative Parameter: Change in MV EVmax. [6, 12, and 24 months, and 3, 4, and 5 years]

   Change in MV EVmax MR severity as assessed by echocardiography in hospital, 6, 12, and 24 months, and 3, 4, and 5 years, in accordance with American Society of Echocardiography guidelines, compared to baseline.

6. Change of MR severity: Semi-Quantitative Parameter: Change in pulmonary vein flow. [6, 12, and 24 months, and 3, 4, and 5 years]

   Change in pulmonary vein flow MR severity as assessed by echocardiography in hospital, 6, 12, and 24 months, and 3, 4, and 5 years, in accordance with American Society of Echocardiography guidelines, compared to baseline.

7. Change in Left Atrial Area [6, 12, and 24 months, and 3, 4, and 5 years]

   Change in Left Atrial Area as assessed by echocardiography at 6, 12, and 24 months, and 3, 4, and 5 years over baseline

8. Change in Left Atrial Diameter [6, 12, and 24 months, and 3, 4, and 5 years]

   Change in Left Atrial Diameter as assessed by echocardiography at 6, 12, and 24 months, and 3, 4, and 5 years over baseline

9. Change in Left Atrial Volume Index [6, 12, and 24 months, and 3, 4, and 5 years]

   Change in Left Atrial Volume as assessed by echocardiography Index at 6, 12, and 24 months, and 3, 4, and 5 years over baseline

10. Change in Left Ventricular End Systolic Volume (LVESV) [6,12, and 24 months, and 3, 4, and 5 years]

    Change in Left Ventricular End Systolic Volume (LVESV) as assessed by echocardiography at 6, 12, and 24 months, and 3, 4, and 5 years over baseline

11. Change in Left Ventricular End Diastolic Volume (LVEDV) [6,12, and 24 months, and 3, 4, and 5 years]

    Change in Left Ventricular End Diastolic Volume (LVEDV) as assessed by echocardiography at 6, 12, and 24 months, and 3, 4, and 5 years over baseline

12. Change in Left Ventricular End Systolic Diameter (LVESD) [6,12, and 24 months, and 3, 4, and 5 years]

    Change in Left Ventricular End Systolic Diameter (LVESD) as assessed by echocardiography at 6, 12, and 24 months, and 3, 4, and 5 years over baseline

13. Change in Left Ventricular End Diastolic Diameter (LVEDD) [6,12, and 24 months, and 3, 4, and 5 years]

    Change in Left Ventricular End Diastolic Diameter (LVEDD) as assessed by echocardiography at 6, 12, and 24 months, and 3, 4, and 5 years over baseline

14. Change in Left Ventricular End Ejection Fraction (LVEF) [6,12, and 24 months, and 3, 4, and 5 years]

    Change in Left Ventricular End Ejection Fraction (LVEF) as assessed by echocardiography at 6, 12, and 24 months, and 3, 4, and 5 years over baseline

15. Change in exercise tolerance by walking [6,12, and 24 months, and 3, 4, and 5 years]

    Change in exercise tolerance as measured by meters walked in Six Minute Walk Test at 6,12, and 24 months, and 3, 4, and 5 years over baseline

16. Change in Quality-of-Life Overall Score [6,12, and 24 months, and 3, 4, and 5 years]

    Change in Quality of Life (QoL) score, as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) at 6,12, and 24 months, and 3, 4, and 5 years over baseline

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Patients with functional mitral regurgitation (i.e., dilated cardiomyopathy), in accordance with CE-mark approved labeling

2. Patients implanted with the Carillon device

3. Patients must be ≥ 18 years old

4. Patients require informed consent prior to inclusion in this registry

5. Minimum baseline data, as described in CINCH Protocol, including:

• Hemodynamic measures (by echocardiography)

• Baseline must include the following measurements: MR grade, LVEF (%), LVEDD, LAD, and AP & ML diameters

• NYHA Classification

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Rheinland Klinikum Neuss GmbH- Lukaskrankenhaus	Neuss		Germany	41464

Sponsors and Collaborators

• Cardiac Dimensions, Inc.

Investigators

• Principal Investigator: Michael Haude, Prof. Dr., Rheinland Klinikum Neuss GmbH Lukaskrankenhaus

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Cardiac Dimensions, Inc.
• ClinicalTrials.gov Identifier: NCT05677568
• Other Study ID Numbers: PMS-1681-01
• First Posted: Jan 10, 2023
• Last Update Posted: Jan 10, 2023
• Last Verified: Dec 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Keywords provided by Cardiac Dimensions, Inc.: Functional Mitral Regurgitation; Mitral Regurgitation; Cardiac Dimensions; Carillon Mitral Contour System; CINCH; CINCH FMR; Carillon; CMCS
• Additional relevant MeSH terms: Mitral Valve Insufficiency

Study Results

No Results Posted as of Jan 10, 2023